Table 3.
Survival analyses comparing the prognostic ability of LCK and CYT
| Cancer subtypea | LCK | Cytolytic Activity Score (CYT) | ||||
|---|---|---|---|---|---|---|
| Median OS bottom 10% (months) | Median OS top 10% (months) | p value | Median OS bottom 10% (months) | Median OS top 10% (months) | p value | |
| ACC | NA | NA | 0.818 | NA | NA | 0.99 |
| BLCA | NA | 94.3 | 0.254 | NA | NA | 0.506 |
| BRCA | 90.4 | 132 | 0.0546 | 84.5 | NA | 0.00293 |
| CESC | 19.4 | NA | 0.000748 | 136 | NA | 0.0121 |
| CHOL | 24.7 | NA | 0.87 | 9.03 | NA | 0.642 |
| COAD | NA | NA | 0.363 | NA | NA | 0.863 |
| ESCA | 42.1 | 26.1 | 0.93 | 26.1 | 16.1 | 0.617 |
| GBM | 13.2 | 12.5 | 0.623 | 13.2 | 10.6 | 0.295 |
| HNSC | 85.7 | 161.9 | 0.0496 | 28.7 | 58.7 | 0.109 |
| KIRC | NA | 66 | 0.497 | NA | 73 | 0.473 |
| KIRP | NA | NA | 0.232 | NA | 98 | 0.591 |
| LAML | 12.2 | 10.1 | 0.118 | 26.4 | 10.2 | 0.0838 |
| LGG | 63 | 63.8 | 0.0269 | 81.1 | 52.6 | 0.0112 |
| LIHC | NA | 54.1 | 0.865 | 59.7 | 56.2 | 0.763 |
| LUAD | 48.5 | 87.2 | 0.368 | 49.7 | 43.1 | 0.664 |
| LUSC | 74.1 | 56 | 0.603 | 74.1 | 61.9 | 0.918 |
| MESO | 17.6 | 13.8 | 0.584 | 25.2 | 13.8 | 0.959 |
| OV | 35.3 | 52.6 | 0.00898 | 52.8 | 49.4 | 0.664 |
| PAAD | NA | 23.4 | 0.687 | 21.7 | 50.1 | 0.973 |
| PCPG | NA | NA | 0.429 | NA | NA | 0.317 |
| PRAD | NA | NA | 0.304 | NA | NA | 0.893 |
| READ | NA | NA | 0.317 | NA | NA | 0.221 |
| SARC | 35.4 | NA | 0.0166 | 41.2 | NA | 0.0323 |
| SKCM | 54.3 | 164.3 | 0.0271 | 58.9 | 164.3 | 0.00509 |
| STAD | 58.2 | 22.3 | 0.857 | 73.2 | NA | 0.936 |
| TGCT | NA | NA | 0.317 | NA | NA | 0.289 |
| THCA | NA | NA | 0.631 | NA | NA | 0.659 |
| UCEC | NA | NA | 0.221 | NA | NA | 0.263 |
| UCS | 22.8 | 30.4 | 0.0358 | 31.6 | NA | 0.804 |
| UVM | NA | NA | 0.808 | NA | NA | 0.806 |
Median overall survival in high LCK expression and low LCK expression as compared to high and low CYT score. High and low groups are defined as top 10% and bottom 10% respectively
aThe following tumor types (project code and n = sample size) were included: adrenocortical carcinoma (ACC, n = 92), bladder/urothelial (BLCA, n = 412), breast invasive carcinoma (BRCA, n = 1098), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC, n = 307), cholangiocarcinoma (CHOL, n = 51), colon adenocarcinoma (COAD, n = 461), esophageal carcinoma (ESCA, n = 185), glioblastoma multiforme (GBM, n = 617), head and neck squamous cell carcinoma (HNSC, n = 528), kidney renal clear cell carcinoma (KIRC, n = 537), kidney renal papillary cell carcinoma (KIRP, n = 291), acute myeloid leukemia (LAML, n = 200), low grade glioma (LGG, n = 516), liver hepatocellular carcinoma (LIHC, n = 377), lung adenocarcinoma (LUAD, n = 585), lung squamous cell carcinoma (LUSC, n = 504), mesothelioma (MESO, n = 87), ovarian serous cystadenocarcinoma (OV, n = 608), pancreatic adenocarcinoma (PAAD, n = 185), pheochromocytoma and paraganglioma (PCPG, n = 179), prostate adenocarcinoma (PRAD, n = 500), rectum adenocarcinoma (READ, n = 172), sarcoma (SARC, n = 261), skin cutaneous melanoma (SKCM, n = 470), stomach adenocarcinoma (STAD, n = 443), testicular germ cell tumors (TGCT, n = 150), thyroid carcinoma (THCA, n = 507), uterine corpus endometrial carcinoma (UCEC, n = 560), uterine carcinosarcoma (UCS, n = 57), and uveal melanoma (UVM, n = 80)